Q-omics provides the consensus-scored ZNF568 profile across patient tissues and cancer cell-line models. ZNF568 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF568 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, ZNF568 RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZNF568 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF568 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF568 survival associations across molecular data types. ZNF568 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF568 RNA expression–survival associations across cancer types. High ZNF568 expression shows unfavorable associations in LGG, but favorable associations in KIRC, HNSC, UCS, BRCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF568 RNA expression.
This table summarizes ZNF568 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF568. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF568 shows lower tumor expression in THCA, HNSC, COAD, UCEC and STAD and higher tumor expression in LIHC. The THCA box plot shows higher ZNF568 RNA expression in normal versus tumor tissue (log2 FC = −0.710, t-test p < 0.001).
This table shows molecular features associated with ZNF568 in patient tissues and cancer cell lines. In patient samples, ZNF568 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF568 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
